Clin2
NCT06567080Possibly a fitNot yet recruiting

JWCAR201 cell therapy for blood cancer or lupus

B-cell TumorsAutoimmune DiseasesLupus Erythematosus, SystemicLarge B-cell Lymphoma

Part of Immune system & allergy, Skin clinical trials.

This trial tests a new treatment called JWCAR201, which uses your own immune cells (a type of CAR-T therapy) to fight either certain blood cancers (large B cell lymphoma) or autoimmune disease (lupus). The goal is to see if this cell therapy can help when standard treatments haven't worked.

Summary written for real people, not researchers, by Clin2.

Phase
Phase 1
Enrollment
15 people
Ages
18 years to 70 years
Study type
Interventional

Who can take part

  • You must be 18 or older (for SLE, up to 70).
  • You have a type of blood cancer called large B cell lymphoma that has come back or not responded to at least two prior treatments, or you have active lupus (SLE).
  • If you have lymphoma, your cancer cells must show a marker called CD20.
  • If you have SLE, you must have tried steroids, immunosuppressants, and biologics, but your disease is still active.
  • You need to have a good level of daily function (able to care for yourself).
  • You cannot have had other cancer for at least 2 years, active infections, or certain heart or brain conditions.

View the official record on ClinicalTrials.gov

Quick eligibility check

Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.

Similar studies

Other trials that look related to this one.

NCT07246096Recruiting· Early Phase 1
CAR-T cell therapy for autoimmune diseases

This trial tests a new CAR-T cell treatment for people with certain autoimmune diseases that have not responded to standard therapies. The treatment uses your own immune cells modified to target and attack disease-causing cells.

Shanghai
NCT07059169Recruiting
CAR-T cell therapy for severe autoimmune diseases

This trial tests a one-time CAR-T cell therapy for people with severe autoimmune diseases like lupus, Sjogren's syndrome, scleroderma, dermatomyositis, or ANCA vasculitis. It aims to reset the immune system and reduce disease activity for those who haven't responded well to standard treatments.

Wuhan, Hubei
NCT07729826Not yet recruiting· Phase 2
CAR T-cell therapy for lupus nephritis that hasn't responded to standard treatment

This trial tests a new treatment called C-CAR168, which uses your own immune cells to target and calm the part of the immune system attacking your kidneys. It is designed for people with lupus nephritis that has not improved with usual treatments.

NCT06685042Recruiting· Phase 1/Phase 2
CAR T-cell therapy for severe autoimmune diseases

This study tests a new treatment called CAR T-cell therapy for people with severe autoimmune diseases that haven't gotten better with standard treatments. The goal is to see if it can help control the disease by reprogramming your immune cells.

Rome, Lazio
NCT06350110Recruiting· Phase 1/Phase 2
CAR T cells for lupus

This trial tests a new type of CAR T cell therapy for people with active lupus that has not responded to other treatments. It uses specially engineered cells to target and eliminate certain immune cells that are causing the disease, with the goal of reducing symptoms and preventing flare-ups.

Beijing, Beijing Municipality
NCT07490951Recruiting
CAR-T cell therapy for refractory autoimmune diseases

This trial tests a personalized cell therapy (CAR-T cells that target CD19 and BCMA proteins) for people with lupus, Sjogren's, scleroderma, dermatomyositis, antisynthetase syndrome, immune-mediated necrotizing myopathy, rheumatoid arthritis, or ANCA-associated vasculitis that has not responded to standard treatments. The goal is to see if this therapy can reduce disease activity.

Wuhan, Hubei

Hear when a new Autoimmune Diseases trial opens

We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.